Phenotypes, genotypes and breakpoints: an assessment of β-lactam/β-lactamase inhibitor combinations against OXA-48.

Tomefa E AsempaAbigail K KoisChristian M GillDavid P Nicolau

Published in: The Journal of antimicrobial chemotherapy (2023)

Data demonstrate that current imipenem/relebactam and ceftazidime/avibactam CLSI breakpoints are appropriate. Data also suggest that higher meropenem/vaborbactam breakpoints relative to meropenem can translate to potentially poor clinical outcomes in patients infected with OXA-48-harbouring isolates.

Keyphrases

gram negative
klebsiella pneumoniae
multidrug resistant
acinetobacter baumannii
electronic health record
escherichia coli
ejection fraction
end stage renal disease
newly diagnosed
big data
drug resistant
patient reported outcomes
machine learning
pseudomonas aeruginosa